INDORE, India, March 26, 2015 /PRNewswire/ --
Glenmark Generics Limited's Pithampur plant near Indore, Madhya Pradesh was recently awarded the 'Outstanding Achievement Awards 2014' for excellence in Health & Safety by The Federation of Madhya Pradesh Chamber of Commerce and Industry (MPFCCI). The recognition was presented by the Honourable Chief Minister of Madhya Pradesh - Shivraj Singh Chauhan at a ceremony in Bhopal.
(Photo: http://photos.prnewswire.com/prnh/20150326/10119193 )
(Logo: http://photos.prnewswire.com/prnh/20130626/625083 )
Glenmark's Pithampur plant bagged the first prize in Health & Safety category among large enterprises. More than 500 participants including the award winners attended the event.
"We are delighted at receiving the award from a prestigious body like MPFCCI. The recognition is a testament of Glenmark's unwavering commitment towards health and safety. Our Pithampur plant has implemented a comprehensive environmental, health and safety system in compliance with ISO 14001 and OHSAS 18001 standards of excellence," said Cheryl Pinto, Director Corporate Affairs - Glenmark.
Certified by OHSAS 18001 and ISO 14001, Glenmark's Pithampur plant has implemented best-in-class health and safety infrastructure, which includes well-equipped occupational health center, fire prevention System, fire detection systems, fire control systems (fire extinguishers and fire hydrant system) and emergency evacuation processes in addition to Standard Operating Procedures including work permit system, safety training, safety committee, employee consultation, incident reporting and many more, apart from formulating a robust Safety Organogram to support health and safety program at the plant.
This state-of-the-art formulations facility manufactures oral solids, semi solids and injectables. It has received approvals from leading regulatory agencies worldwide like the US-FDA and MHRA, UK.
About Glenmark
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 pharma and biotech companies of the world in terms of revenues (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and pain [neuropathic pain and inflammatory pain].
The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. Its subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India. For more information, visit http://www.glenmarkpharma.com/
Media Contact
Corporate Communications
[email protected]
+91-22-40189999
Glenmark Pharmaceuticals
Share this article